Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives

Davidson, Michael; Starling, Naureen

doi:10.2147/ott.s100643

Cited by 22 publications

(17 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to reports, its response rate (RR) ranges from 30% to 60%. 33 – 35 Therefore, even though some EAC patients are defined as HER-2 positive, they do not respond to trastuzumab. Combination treatment including trastuzumab and other therapies for EAC needs further research.…”

Section: Targeting Key Signaling Pathwaysmentioning

confidence: 99%

Advances in targeted therapy for esophageal cancer

Yang

Pan

Xu³

et al. 2020

Sig Transduct Target Ther

299

246

View full text Add to dashboard Cite

Esophageal cancer (EC) is one of the most lethal cancers in the world, and its morbidity and mortality rates rank among the top ten in China. Currently, surgical resection, radiotherapy and chemotherapy are the primary clinical treatments for esophageal cancer. However, outcomes are still unsatisfactory due to the limited efficacy and severe adverse effects of conventional treatments. As a new type of approach, targeted therapies have been confirmed to play an important role in the treatment of esophageal cancer; these include cetuximab and bevacizumab, which target epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), respectively. In addition, other drugs targeting surface antigens and signaling pathways or acting on immune checkpoints have been continuously developed. For example, trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER-2), has been approved by the Food and Drug Administration (FDA) as a first-line treatment of HER-2-positive cancer. Moreover, the PD-L1 inhibitor pembrolizumab has been approved as a highly efficient drug for patients with PD-L1-positive or advanced esophageal squamous cell carcinoma (ESCC). These novel drugs can be used alone or in combination with other treatment strategies to further improve the treatment efficacy and prognosis of cancer patients. Nevertheless, adverse events, optimal dosages and effective combinations still need further investigation. In this review, we expound an outline of the latest advances in targeted therapies of esophageal cancer and the mechanisms of relevant drugs, discuss their efficacy and safety, and provide a clinical rationale for precision medicine in esophageal cancer.

show abstract

Section: Targeting Key Signaling Pathwaysmentioning

confidence: 99%

Advances in targeted therapy for esophageal cancer

Yang

Pan

Xu³

et al. 2020

Sig Transduct Target Ther

299

246

View full text Add to dashboard Cite

show abstract

“…Identification of certain molecular alterations in esophageal tumors could provide targets for existing targeted therapies. For instance, one‐third of the EACs with alterations in the gene ERBB2 (also called HER2 ) might be good candidates for the drug trastuzumab (Herceptin TM ), which blocks the extracellular part of the transmembrane receptor protein product of this gene . However, several studies also recommend that ESCC and EAC should be separated in the clinical setting so that each can be targeted according to its specific genomic features …”

Section: Future Perspectivesmentioning

confidence: 99%

“…For instance, one-third of the EACs with alterations in the gene ERBB2 (also called HER2) might be good candidates for the drug trastuzumab (Herceptin TM ), which blocks the extracellular part of the transmembrane receptor protein product of this gene. 126,127 However, several studies also recommend that ESCC and EAC should be separated in the clinical setting so that each can be targeted according to its specific genomic features. 2,128 Molecular characterization of premalignant esophageal lesions and healthy normal cells from esophageal lining could help to determine early molecular deregulation driving cancer development and progression.…”

Section: Implications For Improving Treatment and Prognosismentioning

confidence: 99%

Molecular landscape of esophageal cancer: implications for early detection and personalized therapy

Talukdar

Pietro

Secrier

et al. 2018

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Esophageal cancer (EC) is one of the most lethal cancers and a public health concern worldwide, owing to late diagnosis and lack of efficient treatment. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are main histopathological subtypes of EC that show striking differences in geographical distribution, possibly due to differences in exposure to risk factors and lifestyles. ESCC and EAC are distinct diseases in terms of cell of origin, epidemiology, and molecular architecture of tumor cells. Past efforts aimed at translating potential molecular candidates into clinical practice proved to be challenging, underscoring the need for identifying novel candidates for early diagnosis and therapy of EC. Several major international efforts have brought about important advances in identifying molecular landscapes of ESCC and EAC toward understanding molecular mechanisms and critical molecular events driving the progression and pathological features of the disease. In our review, we summarize recent advances in the areas of genomics and epigenomics of ESCC and EAC, their mutational signatures and immunotherapy. We also discuss implications of recent advances in characterizing the genome and epigenome of EC for the discovery of diagnostic/prognostic biomarkers and development of new targets for personalized treatment and prevention.

show abstract

“…Interestingly, recent data seem to suggest that HER2 and EGFR are frequently amplified synchronously and preferentially dimerize with one another [8]. As a result, it is not surprising that target therapy with HER2 and EGFR inhibitors have showed promising results as adjuvant treatment options in EC [9,10].…”

Section: Introductionmentioning

confidence: 99%